Deception’s justifiability might depend on clinicians’ commitment to solidarity and awareness of social determinants of patients’ vulnerability to HIV infection.
AMA J Ethics. 2021;23(5):E382-387. doi:
10.1001/amajethics.2021.382.
Rayner Kay Jin Tan, Jane Mingjie Lim, MSW, and Jeremiah Kah Wai Chan, MSc
Merits and drawbacks of U = U messaging are ethically and clinically complex, and drawbacks could harm patients in whom viral suppression is hard to achieve.
AMA J Ethics. 2021;23(5):E418-422. doi:
10.1001/amajethics.2021.418.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Dr Whitney Riley Linsenmeyer joins Ethics Talk to discuss her article, coauthored with Dr Sarah Garwood: “Patient-Centered Approaches to Using BMI to Evaluate Gender-Affirming Surgery Eligibility.”
Lee C. Zhao, MD, Gaines Blasdel, Augustus Parker, and Rachel Bluebond-Langner, MD
Tension between realistic goals and unrealistic views about how to achieve them is compounded when patients are eager to revise a prior surgeon’s gender-affirming procedure.
AMA J Ethics. 2023;25(6):E391-397. doi:
10.1001/amajethics.2023.391.